BIND Therapeutics Now Covered by Analysts at Stifel Nicolaus (BIND)
Equities researchers at Stifel Nicolaus began coverage on shares of BIND Therapeutics (NASDAQ:BIND) in a research report issued on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $20.00 price target on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 30.98% from the stock’s previous close.
The analysts wrote, “We are initiating coverage on BIND Therapeutics, Inc. (BIND) with a Buy rating on the shares and a $20 target price. BIND-014 sales, along with minor contribution from partnership revenue, drive our 2021 BIND revenue estimate of $256 million and our target price estimate. Although we value BIND mainly on BIND-014, we believe the Accurin technology could continue to generate new pipeline products for the next decade.”
Shares of BIND Therapeutics (NASDAQ:BIND) traded up 1.44% during mid-day trading on Tuesday, hitting $15.49. The stock had a trading volume of 48,425 shares. BIND Therapeutics has a 52 week low of $13.99 and a 52 week high of $15.49. The stock has a 50-day moving average of $14.69 and a 200-day moving average of $14.69. The company’s market cap is $244.4 million.
Separately, analysts at Credit Suisse initiated coverage on shares of BIND Therapeutics in a research note to investors on Tuesday. They set an “outperform” rating on the stock.
BIND Therapeutics Inc is a clinical-stage nanomedicine platform company developing Accurins, its targeted and programmable therapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.